▶️Making the C-List Work: Lessons and Next Steps for Pharma
The final Health Policy and Financing Panel wrapped up the C-List Masterclass with reflections, insurer perspectives, global case studies, and Q&A—highlighting how manufacturers can turn C-List inclusion into a true springboard for coverage.
In the closing Health Policy and Financing Panel of the C-List Masterclass, we brought together insights from earlier sessions and looked ahead to what the C-List means for pharma strategies in China.
The discussion explored several critical themes:
- Reflections on prior sessions and how they connect to the evolving C-List landscape.
- Commercial insurers’ perspectives—why their priorities matter for shaping go-to-market strategies and commercial negotiations.
- Practical next steps for manufacturers to make C-List inclusion a genuine springboard for coverage, not just a symbolic listing.
- Two global case studies offering concrete lessons from outside China that pharma can adapt to shape and strengthen their C-List pathway engagement.
- Q&A, where participants raised questions on C-List inclusion priorities, pull-through strategies, and how upcoming reforms may affect multinational vs. local players.
This panel tied the series together with both reflection and forward-looking insights, giving manufacturers pragmatic guidance on how to engage more proactively in China’s emerging multi-level coverage era.
Panelists:
Sejal Mistry
- Senior Director, Crowell Global Advisors; advises on UHC, health financing, and service innovation in Asia-Pacific
- Led Indonesia’s cervical cancer elimination plan
- Former ACCESS Health SEA head
Neil Grubert
- Former VP, Global Market Access Insights, DRG; now independent consultant
- Advised 14 of the top 20 pharma companies worldwide
- Influential LinkedIn voice (25K+ followers); founded Future of Market Access LinkedIn community
Kelly Ke
- Award-winning former Senior Advisor, Deloitte US Life Sciences Practice
- Founder, bizi LLC, an access intelligence consultancy
- Author, NRDL+ Executive Debrief—a widely followed China market access newsletter for global life sciences leaders
💡
China is at an inflection point where policy choices quickly translate into commercial outcomes for manufacturers. Success requires more than tracking headlines—it takes connecting the dots and interpreting them through China’s on-the-ground realities.
